12 / 17
Page 29
Notes:
conferenceseries
.com
Volume 9, Issue 11 (Suppl)
J Cancer Sci Ther
ISSN: 1948-5956 JCST, an open access journal
Asia Pacific Oncologists 2017
November 20-22, 2017
November 20-22, 2017 Melbourne, Australia
14
th
Asia Pacific
Oncologists Annual Meeting
The angiogenic properties of NSC-631570
Wassil Nowicky
Ukrainian Anti-Cancer Institute, Austria
A
nother important feature of medical preparation NSC-631570 after its selective effect (in therapeutic dosage it kills only
cancer cells leaving the healthy cells undamaged) is the inhibition of the formation of the new blood vessels supplying a
tumor. Due to these anti-angiogenic properties NSC-631570 administered before surgery brings about better demarcation of
the tumor from surrounding tissue and the tumor encapsulation. This alleviates the surgical removal of tumors what has been
confirmed in breast cancer studies. In
in vitro
tests; NSC-631570 inhibited in a dose dependent manner, the proliferation of
human endothelial cells without exerting cytotoxic effect. The angiogenesis inhibition was observed on the capillary formation
model. This inhibition of the neoangeogenesis prevents the metastasis formation as well.
Biography
Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He is the author of over 300 scientific
articles dedicated to cancer research. He is the Member of the New York Academy of Sciences, Member of the European Union for Applied Immunology and the
American Association for Scientific Progress, Honorary Doctor of the Janka Kupala University in Hrodno, Doctor Honoris Causa of the Open International University
on Complex Medicine in Colombo, Honorary Member of the Austrian Society. He has received the award for Merits of National Guild of Pharmacists of America,
the award of Austrian Society of Sanitary, Hygiene and Public Health Services and others.
dr.nowicky@yahoo.deWassil Nowicky, J Cancer Sci Ther 2017, 9:11 (Suppl)
DOI: 10.4172/1948-5956-C1-117